The Future of ADCs: Earlier Use, Smarter Selection, and Adaptive Care

This final segment looks ahead to the future of ADCs in breast cancer, highlighting their expanding role across disease stages and subtypes. Experts anticipate increasing use of ADCs in earlier lines of therapy, including the neoadjuvant and early-stage settings, with the potential to reduce reliance on intensive chemotherapy. Ongoing trials in early TNBC are particularly promising, as ADC-based strategies may allow meaningful treatment de-escalation while maintaining efficacy.

Innovation in ADC design is another major area of progress. Next-generation platforms incorporating novel payloads, improved linker technologies, and dual-target or bispecific approaches may enhance activity and help overcome resistance. These advances could also improve sequencing strategies by enabling the use of ADCs with distinct mechanisms of action. Emerging technologies such as artificial intelligence-assisted pathology and biomarker-driven risk stratification may further refine patient selection and support more adaptive treatment approaches.

At the same time, the rapid pace of new data presents practical challenges. Clinicians must balance enthusiasm for highly active therapies with careful attention to cumulative toxicity and treatment burden. The overarching goal is to use ADCs more strategically by selecting the right agent for the right patient at the right time.

The discussion concludes with a pragmatic message for clinicians: the field is evolving quickly, and uncertainty is expected. Leveraging guidelines, collaborating with colleagues, and staying engaged with emerging evidence will be essential as ADCs continue to reshape breast cancer care across the disease continuum.